Methods for targeting pulmonary diseases with agents that bind a target in pulmonary tissue
Disclosed is the use of an agent (e.g., antibody fragment, antagonist, ligand, dAb monomer) that binds a target in pulmonary tissue for the manufacture of a long action or long therapeutic window formulation for local delivery to pulmonary tissue, and methods for administering an agent that binds a target in pulmonary tissue to a subject to produce a long therapeutic window in pulmonary tissue. The formulation is for, and the method comprises, administering locally to pulmonary tissue. Also disclosed is the use of antagonists of TNFR1 for the manufacture of a formulation or medicament for treating, preventing or suppressing lung inflammation or a respiratory disease, and methods of treating such diseases. Also disclosed are the use of agents a for the manufacture of a delivery device (e.g., inhaler, intranasal delivery device) for the treatment or prevention of lung inflammation or a respiratory disease, and a delivery device for the treatment or prevention of lung inflammation or a respiratory disease that contains an agent as described herein.
1. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a ligand that comprises a domain antibody comprising a CDR1 amino acid sequence, a CDR2 amino acid sequence and a CDR3 amino acid sequence of the domain antibody having the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.
2. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a domain antibody that binds TNFR1, wherein the domain antibody is an antagonist of the TNFR1 and comprises a CDR1 amino acid sequence, a CDR2 amino acid sequence and a CDR3 amino acid sequence of the domain antibody having the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.
3. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a domain antibody that comprises a CDR1 amino acid sequence, a CDR2 amino acid sequence and a CDR3 amino acid sequence of the domain antibody having the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.
4. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a domain antibody that binds TNFR1, wherein the domain antibody is an antagonist of the TNFR1 and comprises the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.
5. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a domain antibody that comprises the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.
6. A method for treating chronic obstructive pulmonary disease in a patient comprising the steps of:
a) identifying a patient with chronic obstructive pulmonary disease;
b) providing a formulation comprising a ligand that comprises an immunoglobulin single variable domain that binds TNFR1; wherein the amino acid sequence of the immunoglobulin single variable domain comprises CDR1, CDR2 and CDR3 amino acid sequences derived from the amino acid sequence shown in SEQ ID NO: 379; wherein the first three amino proximal residues of CDR1 comprise up to two amino acid substitutions in CDR1 from the amino acid sequence shown in SEQ ID NO: 379; wherein CDR2 has at least about 80% identity to CDR2 of the amino acid sequence shown in SEQ ID NO: 379; and wherein CDR3 is the same as CDR3 of the amino acid sequence shown in SEQ ID NO: 379; and
c) administering the formulation locally to pulmonary tissue of the patient in an effective amount;
whereby the chronic obstructive pulmonary disease in the patient is treated.